Ho tloha moo ho lokolloeng ha "ba 14 ho isa ho la 14 Hlakubele Litaba tse amanang le sethethefatsi sa R & D tsa ho fihlella, indasteri ea masale, le tumello ea ho tsamaisana le eona e fetile "ho etsa hore" Ka ho matlafatsa bokhoni ba eona bo tsitsitseng le R & D, indasteri e atolohile haholo 'me e fetohile mokhanni oa bohlokoa oa tsoelo-pele ea theknoloji ea moruo.
Bakeng sa ho ntlafatsa ntlafatso le tšebelisano 'moho tšimong ea biotechnology Chaena, ka la 4 Mmesa Ketsahalo ena e bokelletse likolo tse ngata le litsebi tsa litsebi tsa indastering ea ho buisana le litlotla tsa bitechnology le ka nako e tlang.
Jiangsu Hillgene Biopharma Co, Ltd (e bitsoa "Hillgegene") e rometsoe haholo le ho rorisoa ka bongata lebaleng la Cell Therapy Senype (CDMO). Ho latela tlhahlobo e felletseng, ho kenyelletsa tlhahlobo ea litokomane, khetho le Patlisiso ea tšimo e entsoeng ke KPMG China le setsebi
Ho ahlola Komiti, matla a sekoli le katleho e fumanoeng haholo ho baahloli ba ba etsang lipatlisiso, qetellong ba fumana lenane la 2 la biog.
Ts'ebetso ena ea khetho e ne e kenyelletsa ho hlahloba likhoebo tse tsoang maemong a fapaneng, ho kenyelletsa tlholisano ea Lihlahisoa, Mefuta ea Litaba tsa Bokhopo le Bophelo ba Liikoloho. Morero ke ho khetha likhoebo tse ts'episang tse tharo tse ka tlatsetsang khoebong ea bo-rahistori tsa bo-ramahlale, le ho etsa sethala sa ho arolelana setaelehong ho tlamahane, le ntlafatso ea indasteri le ntlafatso ea indasteri.
Nako: 2023 - 05 - 29 00:00:00
